Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-GPRC5D/anti-CD3 bispecific antibody LBL-034

A humanized immunoglobulin G1 (IgG1) bispecific monoclonal antibody directed against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential immunomodulating and antineoplastic activities. Upon administration, anti-GPRC5D/anti-CD3 bispecific antibody LBL-034 binds to both CD3 on T cells and GPRC5D expressed on tumor cells. This results in the cross-linking of T cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors while minimally expressed on normal, healthy cells. It plays a key role in tumor cell proliferation.
Synonym:anti-CD3/anti-GPRC5D bispecific monoclonal antibody LBL-034
anti-GPRC5D/CD3 bispecific antibody LBL-034
GPRC5D x CD3 bispecific antibody LBL-034
Code name:LBL 034
LBL-034
LBL034
Search NCI's Drug Dictionary